Holen Sie sich die Stockscreener-App
82.83
2.44%
2.125
Schlusskurs vom Vortag:
$80.71
Offen:
$79.88
24-Stunden-Volumen:
84,652
Relative Volume:
0.12
Marktkapitalisierung:
$6.81B
Einnahmen:
$39.21M
Nettoeinkommen (Verlust:
$-311.35M
KGV:
-22.51
EPS:
-3.6793
Netto-Cashflow:
$-234.34M
1W Leistung:
-4.62%
1M Leistung:
-3.19%
6M Leistung:
+38.01%
1J Leistung:
+134.35%
1-Tages-Spanne:
$79.18
$83.02
1-Wochen-Bereich:
$77.64
$88.39
52-Wochen-Spanne:
$28.06
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
82.79 | 6.64B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
427.62 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.28 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.49 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.88 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.12 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics Q1 2026 earnings preview - MSN
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail
Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates - MSN
Kymera Q1 2026 slides: immunology pipeline advances, revenue surges By Investing.com - Investing.com Australia
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - GuruFocus
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat
Kymera Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Key Risks and Forward-Looking Statements in Kymera Therapeutics, Inc. Q1 2026 10-Q Report - Minichart
Kymera Therapeutics Q1 Earnings Call Highlights - MarketBeat
Kymera Therapeutics Reports Q1 2026 Financial Results, Highlights Pipeline Progress and $1.55B Cash Runway into 2029 - Minichart
Kymera shifts KT-579 data to 2H 2026, keeps KT-621 on track - MSN
Kymera Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts By Investing.com - Investing.com Australia
Kymera Therapeutics (KYMR) Achieves Strong Q1 Revenue Performanc - GuruFocus
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts - Investing.com
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Investing News Network
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Is Kymera Therapeutics (KYMR) 418.1% Overvalued After Q1 2026 Be - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat - ChartMill
Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) grows collaboration revenue but stays in loss - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Kymera has $1.55B to fund asthma and dermatitis drug trials - Stock Titan
Pictet Asset Management Holding SA Has $37.79 Million Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative - Sahm
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock - MarketBeat
Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock - Investing.com
Kymera (KYMR) CEO Mainolfi exercises options and sells 30,000 shares under 10b5-1 plan - Stock Titan
[ARS] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) outlines 2026 director, pay and auditor votes - Stock Titan
Kymera Therapeutics earnings on deck after Gilead deal milestone - Investing.com UK
Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com South Africa
How Investors May Respond To Kymera Therapeutics (KYMR) FDA Fast Track Win And Gilead Trial Expansion - simplywall.st
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q1 202 - GuruFocus
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 - Investing News Network
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):